LFA Opportunities Fortis Life Sciences has dedicated antibodies and antigens for lateral flow assay applications and recently launched LFA kits with Au nanoparticles achieving up to 20x sensitivity. This signals strong potential to partner with diagnostic developers, contract manufacturers, and point-of-care firms for high-sensitivity reagents, conjugates, and validated controls.

Global Footprint The company expanded offices to Seoul and appointed APAC leadership, indicating emphasis on Asia-Pacific markets. Sales opportunities include regional distribution partnerships, localized technical support, and supply-chain agreements to serve growing R&D ecosystems in APAC.

Validated Applications In-house antibodies are manufactured and affinity purified with validation across ELISA, Western blot, IP, ChIP, PLA, IHC, and ICC, plus a portfolio for immunology, oncology, neuroscience, and cardiovascular disease. This enables cross-selling of validated antibodies and reagents to CROs, pharma, and academic labs needing ready-to-use panels for multiple workflows.

Growth Partnerships Recent partnerships and investments, including Deliver Bio collaboration for AbNano VHH discovery and Astraea Bio partnership, align with a strategy to expand discovery capabilities and spatial biology. Sales can target joint-development opportunities and provide specialized nanobody reagents or custom discovery services.

Quality and Scale With antibody manufacturing and affinity purification performed in-house, Fortis Life Sciences can offer reliable supply, custom antibody development and conjugation, and high-quality controls for diagnostic and research use, appealing to customers seeking consistent lots and regulatory-ready reagents.